Table 2: Prior treatments.
| Number of patients (%) | |
| Adjuvant or neoadjuvant therapies | |
| Anthracycline | 26 (41%) |
| Taxane | 22 (35%) |
| Trastuzumab | 19 (30%) |
| Endocrine therapy | 21 (33%) |
| Previous anti-HER2 therapies for metastatic breast cancer | |
| Trastuzumab | 61 (97%) |
| Pertuzumab | 41 (65%) |
| Lapatinib | 21 (33%) |
| Number of previous regimens for metastatic breast cancer | |
| 0 (first line) | 0 (0%) |
| 1 (second line) | 17 (27%) |
| 2 (third line) | 8 (13%) |
| 3 (forth line) | 12 (19%) |
| ≥ 4 | 26 (41%) |
| Median time since first-line treatment of metastatic breast cancer, months (range) | 29 (6-217) |